AEON Biopharma, Inc. Files FORM 8-K: Annual Meeting Results and Regulatory Filings

Strategic Insights -

AEO Biopharma, Inc. held its Annual Meeting of Stockholders on June 13, 2025, where two proposals were voted on by stockholders. The outcomes of these proposals have been made public through the filing of FORM 8-K with the U.S. Securities and Exchange Commission. The company has also disclosed its financial performance for the fiscal year ended December 31, 2025. The results of these proposals provide insight into the company's leadership and financial decisions.

Key Takeaways:

  • Jost Fischer and Eric Carter were elected as Class II directors of the company's board of directors for a three-year term ending at the Annual Meeting of Stockholders in 2028, with 661,774 and 674,894 votes, respectively.
  • 138,295 and 125,175 stockholders voted against the election of Jost Fischer and Eric Carter, respectively.
  • The stockholders ratified the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ended December 31, 2025, with 4,956,438 votes in favor and 170,672 against.
  • The certificate of registration and other filings related to the annual meeting were submitted by the CEO, Robert Bancroft, on June 13, 2025.

Statistics:

  • 661,774 stockholders voted for Jost Fischer's election as Class II director.
  • 138,295 stockholders voted against Jost Fischer's election.
  • 674,894 stockholders voted for Eric Carter's election as Class II director.
  • 125,175 stockholders voted against Eric Carter's election.
  • 4,956,438 stockholders ratified the appointment of KPMG LLP as independent registered public accounting firm.
  • 170,672 stockholders abstained from voting on KPMG's appointment.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025
  • Securities and Exchange Act of 1934 (17 CFR 240.14d-2(b))